BR0114696A - Uso de antiprogestinas para a indução de apoptose em uma célula - Google Patents

Uso de antiprogestinas para a indução de apoptose em uma célula

Info

Publication number
BR0114696A
BR0114696A BR0114696-3A BR0114696A BR0114696A BR 0114696 A BR0114696 A BR 0114696A BR 0114696 A BR0114696 A BR 0114696A BR 0114696 A BR0114696 A BR 0114696A
Authority
BR
Brazil
Prior art keywords
cell
antiprogestins
antiprogestin
estra
acetylphenyl
Prior art date
Application number
BR0114696-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Jens Hoffmann
Rosemarie Lichtner
Gerd Siemeister
Martin Schneider
Ulrike Fuhrmann
Original Assignee
Schering Aktiengellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengellschaft filed Critical Schering Aktiengellschaft
Publication of BR0114696A publication Critical patent/BR0114696A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0114696-3A 2000-10-18 2001-10-17 Uso de antiprogestinas para a indução de apoptose em uma célula BR0114696A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24099100P 2000-10-18 2000-10-18
EP00250342 2000-10-18
PCT/EP2001/012006 WO2002032432A1 (en) 2000-10-18 2001-10-17 Use of antiprogestins for the induction of apoptosis in a cell

Publications (1)

Publication Number Publication Date
BR0114696A true BR0114696A (pt) 2003-11-18

Family

ID=26072952

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114696-3A BR0114696A (pt) 2000-10-18 2001-10-17 Uso de antiprogestinas para a indução de apoptose em uma célula

Country Status (28)

Country Link
EP (1) EP1326617B9 (https=)
JP (1) JP2004511523A (https=)
KR (1) KR100668024B1 (https=)
CN (1) CN1209111C (https=)
AT (1) ATE334683T1 (https=)
AU (2) AU2002223619B2 (https=)
BG (1) BG107744A (https=)
BR (1) BR0114696A (https=)
CA (1) CA2423020C (https=)
CY (1) CY1105745T1 (https=)
CZ (1) CZ299823B6 (https=)
DE (1) DE60121980T2 (https=)
DK (1) DK1326617T3 (https=)
EA (1) EA010593B1 (https=)
EE (1) EE200300157A (https=)
ES (1) ES2269492T3 (https=)
HR (1) HRP20030388A2 (https=)
HU (1) HUP0301433A3 (https=)
IL (2) IL154976A0 (https=)
MX (1) MXPA03002955A (https=)
NO (1) NO20031741L (https=)
NZ (1) NZ538347A (https=)
PL (1) PL360157A1 (https=)
PT (1) PT1326617E (https=)
SI (1) SI1326617T1 (https=)
SK (1) SK4702003A3 (https=)
UA (1) UA76729C2 (https=)
WO (1) WO2002032432A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
WO2008128786A1 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
EP2136796A2 (en) * 2007-04-23 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
JP6092880B2 (ja) * 2011-10-04 2017-03-08 インヴァイヴィス ファーマスーティカルズ インコーポレーテッドInvivis Pharmaceuticals Inc. 抗プロゲスチン感受性腫瘍を特定および治療する方法ならびに系

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Also Published As

Publication number Publication date
EP1326617B9 (en) 2006-10-25
HRP20030388A2 (en) 2005-04-30
ES2269492T3 (es) 2007-04-01
EA010593B1 (ru) 2008-10-30
IL154976A0 (en) 2003-10-31
DK1326617T3 (da) 2006-12-18
CZ299823B6 (cs) 2008-12-03
EE200300157A (et) 2003-08-15
DE60121980D1 (de) 2006-09-14
HK1062273A1 (en) 2004-10-29
MXPA03002955A (es) 2003-08-07
DE60121980T2 (de) 2007-03-01
IL154976A (en) 2007-05-15
EA200300479A1 (ru) 2003-10-30
EP1326617A1 (en) 2003-07-16
CA2423020A1 (en) 2002-04-25
HUP0301433A2 (hu) 2003-10-28
ATE334683T1 (de) 2006-08-15
KR100668024B1 (ko) 2007-01-15
CA2423020C (en) 2009-01-20
BG107744A (bg) 2004-02-27
CN1209111C (zh) 2005-07-06
UA76729C2 (uk) 2006-09-15
NO20031741L (no) 2003-06-17
CY1105745T1 (el) 2010-12-22
WO2002032432A1 (en) 2002-04-25
PL360157A1 (en) 2004-09-06
EP1326617B1 (en) 2006-08-02
NZ538347A (en) 2007-03-30
SI1326617T1 (sl) 2007-02-28
PT1326617E (pt) 2006-12-29
SK4702003A3 (en) 2004-01-08
AU2002223619B2 (en) 2006-08-24
AU2361902A (en) 2002-04-29
HUP0301433A3 (en) 2010-01-28
KR20030057540A (ko) 2003-07-04
NO20031741D0 (no) 2003-04-15
CN1469749A (zh) 2004-01-21
JP2004511523A (ja) 2004-04-15

Similar Documents

Publication Publication Date Title
BR0114665A (pt) Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
DK1071439T3 (da) Hybenformuleringer som antiinflammatorisk naturmedicin til lindring/reduktion af symptomer associeret med inflammation og artritis
BR0114696A (pt) Uso de antiprogestinas para a indução de apoptose em uma célula
BR0307041A (pt) Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes
ES507836A0 (es) Procedimiento para la obtencion de un extracto total de he- dysarum fructescens willd.
BR0214798A (pt) Uso de anastrozol ou um sal farmaceuticamente aceitável do mesmo, e, métodos para reduzir a taxa de recorrência de câncer e a taxa de um novo tumor primário contralateral em uma mulher pós-menopausa tendo câncer de mama em estado inicial
BR0313411A (pt) Uso de reboxetina para o tratamento de ondas de calor
ECSP034606A (es) Uso de antiprogestinas para la induccion de apoptosis en una celula
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
IT1241079B (it) Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
BR9908885A (pt) Medicamento para a profilaxia e/ou tratamento de mastocarcinoma, compreendendo um inibidor esteróide de aromatase
NZ504351A (en) Contraceptive kit comprising progestogen and anti-progestogen and use in treating bleeding induced by a progestogen-only contraceptive regimen
IL129267A (en) Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence
BRPI0606724A2 (pt) preparação farmacêutica para contracepção
CL2004000579A1 (es) Uso de dienogest para preparar composiciones farmaceuticas destinadas a reducir el cuerpo de la glandula mamaria.
YU30103A (sh) Upotreba antiprogestina za profilaksu i lečenje hormonski zavisnih bolesti
Denham Prostate cancer: low α/β the only consideration? In regard to Fowler, Chappell, and Ritter: the prospects for new treatments for prostate cancer. IJROBP 2002; 52: 3–5
BR0010070A (pt) Uso de org 33245, kit contraceptivo, meio combinado para a dosagem de um progestogênio e um antiprogestogênio, e, métodos de contracepção, e de tratamento de sangramento uterino irregular ou de ruptura em uma fêmea utilizando uma preparação somente de progestogênio
SI1937274T1 (sl) Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo
ES2113106T3 (es) Esteres de 14alfa,15alfa-metilen-estradiol con efecto estrogeno administrables por via oral.
BRMU8400115U (pt) Calcinha higiênica para mulheres em geral
CO5280075A1 (es) Drospirenona para terapia de reemplazo de hormonas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]